These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1013 related articles for article (PubMed ID: 8875929)

  • 1. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.
    Kussie PH; Gorina S; Marechal V; Elenbaas B; Moreau J; Levine AJ; Pavletich NP
    Science; 1996 Nov; 274(5289):948-53. PubMed ID: 8875929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain.
    Popowicz GM; Czarna A; Holak TA
    Cell Cycle; 2008 Aug; 7(15):2441-3. PubMed ID: 18677113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening of medicinal plant phytochemicals as natural antagonists of p53-MDM2 interaction to reactivate p53 functioning.
    Riaz M; Ashfaq UA; Qasim M; Yasmeen E; Ul Qamar MT; Anwar F
    Anticancer Drugs; 2017 Oct; 28(9):1032-1038. PubMed ID: 28723868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding.
    Uhrinova S; Uhrin D; Powers H; Watt K; Zheleva D; Fischer P; McInnes C; Barlow PN
    J Mol Biol; 2005 Jul; 350(3):587-98. PubMed ID: 15953616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-terminal 130 amino acids of MDM2 are sufficient to inhibit p53-mediated transcriptional activation.
    Leng P; Brown DR; Shivakumar CV; Deb S; Deb SP
    Oncogene; 1995 Apr; 10(7):1275-82. PubMed ID: 7731677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
    Pazgier M; Liu M; Zou G; Yuan W; Li C; Li C; Li J; Monbo J; Zella D; Tarasov SG; Lu W
    Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4665-70. PubMed ID: 19255450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo.
    Shimizu H; Burch LR; Smith AJ; Dornan D; Wallace M; Ball KL; Hupp TR
    J Biol Chem; 2002 Aug; 277(32):28446-58. PubMed ID: 11925449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of the p53-MDM2 interaction by phosphorylation of Thr18: a computational study.
    Lee HJ; Srinivasan D; Coomber D; Lane DP; Verma CS
    Cell Cycle; 2007 Nov; 6(21):2604-11. PubMed ID: 17957142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Over-expression of the human MDM2 p53 binding domain by fusion to a p53 transactivation peptide.
    Liu Z; Olejniczak ET; Fesik SW
    Protein Expr Purif; 2004 Oct; 37(2):493-8. PubMed ID: 15358376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular basis for the inhibition of p53 by Mdmx.
    Popowicz GM; Czarna A; Rothweiler U; Szwagierczak A; Krajewski M; Weber L; Holak TA
    Cell Cycle; 2007 Oct; 6(19):2386-92. PubMed ID: 17938582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Filling in the blanks in the p53 protein structure.
    Pennisi E
    Science; 1996 Nov; 274(5289):921-2. PubMed ID: 8966571
    [No Abstract]   [Full Text] [Related]  

  • 12. Structural details on mdm2-p53 interaction.
    Chi SW; Lee SH; Kim DH; Ahn MJ; Kim JS; Woo JY; Torizawa T; Kainosho M; Han KH
    J Biol Chem; 2005 Nov; 280(46):38795-802. PubMed ID: 16159876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding induced folding in p53-MDM2 complex.
    Chen HF; Luo R
    J Am Chem Soc; 2007 Mar; 129(10):2930-7. PubMed ID: 17302414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repression of p53-mediated transcription by MDM2: a dual mechanism.
    Thut CJ; Goodrich JA; Tjian R
    Genes Dev; 1997 Aug; 11(15):1974-86. PubMed ID: 9271120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The tumor suppressor p53 and the oncoprotein simian virus 40 T antigen bind to overlapping domains on the MDM2 protein.
    Brown DR; Deb S; Muñoz RM; Subler MA; Deb SP
    Mol Cell Biol; 1993 Nov; 13(11):6849-57. PubMed ID: 8413278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A site-directed mutagenesis study of the MdmX RING domain.
    Egorova O; Mis M; Sheng Y
    Biochem Biophys Res Commun; 2014 May; 447(4):696-701. PubMed ID: 24755078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis for the conserved binding mechanism of MDM2-inhibiting peptides and anti-apoptotic Bcl-2 family proteins.
    Lee MS; Ha JH; Yoon HS; Lee CK; Chi SW
    Biochem Biophys Res Commun; 2014 Feb; 445(1):120-5. PubMed ID: 24491548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural convergence of unstructured p53 family transactivation domains in MDM2 recognition.
    Shin JS; Ha JH; Lee DH; Ryu KS; Bae KH; Park BC; Park SG; Yi GS; Chi SW
    Cell Cycle; 2015; 14(4):533-43. PubMed ID: 25591003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of specificity of MDM2 for the activation domains of p53 and p65: proline27 disrupts the MDM2-binding motif of p53.
    Zondlo SC; Lee AE; Zondlo NJ
    Biochemistry; 2006 Oct; 45(39):11945-57. PubMed ID: 17002294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of a retroinverso p53 peptide as an inhibitor of MDM2.
    Sakurai K; Chung HS; Kahne D
    J Am Chem Soc; 2004 Dec; 126(50):16288-9. PubMed ID: 15600307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.